Vaniqa
This article was originally published in The Rose Sheet
Executive Summary
Second round of national TV ads launching now and print ads debuting in April focus on educating women who remove unwanted facial hair rather than building brand awareness as the first campaign did, Bristol Myers Squibb said during Feb. 22 press event. Co-marketed by Gillette, Rx topical cream (13.9% eflornithine) debuted in September (1"The Rose Sheet" Aug. 7, 2000, p. 6). Second round of ads will feature close-up shots of women applying the cream and an illustration of how product effects the hair follicle
You may also be interested in...
Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate
Ongoing studies on Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the target consumer of the topical cream to include men. FDA approved the product for removal of women's facial hair July 27.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle